← Product Code [LFR](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/LFR) · K110587

# CONTOUR LINK BLOOD GLUCOSE METER, CONTOUR BLOOD GLUCOSE TEST STRIPS, CONTOUR CONTROL SOLUTION (HIGH, NORMAL, LOW) (K110587)

_Bayer Healthcare, LLC · LFR · Mar 28, 2012 · Clinical Chemistry · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/LFR/K110587

## Device Facts

- **Applicant:** Bayer Healthcare, LLC
- **Product Code:** [LFR](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/LFR.md)
- **Decision Date:** Mar 28, 2012
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.1345
- **Device Class:** Class 2
- **Review Panel:** Clinical Chemistry
- **Attributes:** Pediatric

## Indications for Use

The CONTOUR® LINK Wireless Blood Glucose Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single-patient use only and should not be shared. The CONTOUR® LINK Wireless Blood Glucose Monitoring System is indicated for use with fresh capillary whole blood samples drawn from the fingertip only. CONTOUR® test strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL. The CONTOUR® LINK Wireless Blood Glucose Monitoring System is intended to be used to transmit glucose values to Medtronic MiniMed Paradigm Insulin Pumps or Medtronic MiniMed Paradigm REAL-Time Revel Insulin Pumps through use of radio frequency communication. The CONTOUR® LINK Wireless Blood Glucose Monitoring System is not intended for the diagnosis of or screening for diabetes mellitus and is not intended for use on neonates.

## Device Story

System consists of CONTOUR LINK meter, test strips, lancing device, and control solution; measures blood glucose via amperometric technology using FAD-glucose dehydrogenase enzyme. User applies capillary blood sample to test strip; meter provides quantitative glucose result in 5 seconds. Device features RF wireless transmission to compatible Medtronic MiniMed Paradigm insulin pumps. Used in home settings by patients for self-monitoring; output assists in insulin dosing decisions. Benefits include automated data transfer to insulin pump, reducing manual entry errors and facilitating diabetes management.

## Clinical Evidence

Method comparison study performed with 100 diabetic subjects using 400 samples (fresh and manipulated capillary blood). Comparison against YSI 2300 STAT PLUS analyzer. Results showed 98.5% of readings met ISO 15197 accuracy criteria (within ±15 mg/dL for <75 mg/dL and ±20% for ≥75 mg/dL). Precision evaluated via within-run and between-day studies; %CV ranged from 1.5% to 4.2%.

## Technological Characteristics

Amperometric glucose measurement using FAD-glucose dehydrogenase enzyme. Measurement range 20-600 mg/dL. Connectivity via RF wireless transmission to Medtronic insulin pumps. No coding required. Hematocrit range 20-65%. Sample type: capillary whole blood (fingertip only).

## Regulatory Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

## Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

## Predicate Devices

- CONTOUR Blood Glucose Meter ([K062058](/device/K062058.md))
- OneTouch UltraLink Blood Glucose Meter ([K073231](/device/K073231.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number:
k110587

B. Purpose for Submission:
Modified device (Addition of the radio frequency transmitter to the previously cleared Contour blood glucose monitoring system under k062058)

C. Measurand:
Capillary whole blood glucose

D. Type of Test:
Quantitative, Amperometric method, Glucose dehydrogenase (FAD)

E. Applicant:
Bayer HealthCare LLC, Diabetes Care

F. Proprietary and Established Names:
CONTOUR® Link Wireless Blood Glucose Monitoring System

G. Regulatory Information:
|  Product Code | Classification | Regulation Section | Panel  |
| --- | --- | --- | --- |
|  LFR – Glucose dehydrogenase, glucose | Class II | 21 CFR § 862.1345 | 75- Chemistry  |
|  NBW – system, test, blood glucose, over the counter | Class II | 21 CFR § 862.1345 | 75- Chemistry  |

H. Intended Use:
1. Intended use(s):
See indications for use below.
2. Indication(s) for use:

{1}

The CONTOUR® LINK Wireless Blood Glucose Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single-patient use only and should not be shared. The CONTOUR® LINK Wireless Blood Glucose Monitoring System is indicated for use with fresh capillary whole blood samples drawn from the fingertip only.

CONTOUR® test strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL.

The CONTOUR® LINK Wireless Blood Glucose Monitoring System is intended to be used to transmit glucose values to Medtronic MiniMed Paradigm Insulin Pumps or Medtronic MiniMed Paradigm REAL-Time Revel Insulin Pump.

The CONTOUR® LINK Wireless Blood Glucose Monitoring System is not intended for the diagnosis of or screening for diabetes mellitus and is not intended for use on neonates.

3. Special conditions for use statement(s):

For over-the-counter use and for prescription use.

For single-patient use only.

For use with capillary whole blood samples drawn from the fingertip.

Not for neonatal use, not for screening or diagnosis of diabetes mellitus.

May be used to transmit glucose values to compatible Medtronic MiniMed devices through use of radio frequency communication.

Not for use on critically ill patients (e.g. those with severe hypotension or shock, hyperglycemic-hyperosmolar state, hypoxia, severe dehydration, diabetic ketoacidosis).

4. Special instrument requirements:

Contour Link Wireless Blood Glucose Meter

I. Device Description:

The CONTOUR® Link Wireless is a blood glucose meter equipped with an RF transmission device allowing transfer of blood glucose measurements to compatible Medtronic diabetes devices.

2

{2}

The internal detailed design of the CONTOUR® Link Wireless meter that executes the blood glucose measurement is based on technology already established with Bayer's CONTOUR® meter. The CONTOUR® Link Wireless system also uses existing CONTOUR® test strips and control solutions from Bayer. The methods for measuring glucose, including algorithms, temperature compensation, and User interface (UI) are equivalent between the CONTOUR® Link meter and the CONTOUR® meter. Results of blood glucose tests are stored within the meter. The CONTOUR® Link Wireless system also contains an RF daughter board that allows transmission of blood glucose results to compatible Medtronic MiniMed devices.

The CONTOUR® Link Wireless Blood Glucose Monitoring System consists of the following components:
- CONTOUR® Link Wireless Blood Glucose Meter
- CONTOUR® blood glucose test strips – 10 ct (cleared in k062058)
- CONTOUR® control solutions (three levels, cleared in k062058)

J. Substantial Equivalence Information:

1. Predicate device name(s):

Bayer's CONTOUR® Blood Glucose Monitoring System (k062058)

2. Predicate K number(s):

k062058

3. Comparison with predicate:

|  Item | Candidate device
Bayer's Contour Link Wireless | Predicate device
Bayer's Contour (k062058)  |
| --- | --- | --- |
|  Intended Use/Indications for Use | Same | For the quantitative measurement of glucose in whole blood.  |
|   |  Over-the-counter (OTC) device used by persons with diabetes in home settings.
For single patient use only. | Over-the-counter (OTC) device used by persons with diabetes and by healthcare professionals in home settings and in healthcare facilities.  |
|   |  Capillary samples only.
Not for use on neonates. | For use with capillary, venous, and arterial whole blood samples and neonatal blood samples.  |
|   |  Fingertip samples only. | Capillary samples may be drawn from the fingertip, palm, forearm, and in the case of neonates, the heel.  |

{3}

|   | May be used to transmit glucose values to compatible Medtronic MiniMed devices through use of radio frequency communication. | No RF capability  |
| --- | --- | --- |
|  Hardware/software for Glucose measurement | Same | Design used in Contour meter  |
|  Detection method | Same | Amperometry  |
|  Test strip | Same | CONTOUR test strip  |
|  Test strip enzyme | Same | Glucose Dehydrogenase FAD  |
|  Controls | Same | Bayer glucose control solutions  |
|  Calibration Coding | Same | No coding by user  |
|  Test range | 20 - 600 mg/dL | 10-600 mg/dL  |
|  Sample volume | Same | 0.6 μL  |
|  Power supply | Same | Two 3V Li battery (CR2032 or DL2032)  |
|  Memory | Same | Most recent 480 test results  |

# K. Standard/Guidance Document Referenced (if applicable):

None were referenced.

# L. Test Principle:

The CONTOUR®Link Wireless blood glucose test is based on measurement of electrical current caused by the reaction of glucose with the reagents on the electrode of the strip. The blood sample is drawn into the tip of the test strip through capillary action. Glucose in the sample reacts with FAD glucose dehydrogenase (FAD-GDH) and potassium ferricyanide. Electrons are generated, producing a current that is proportional to the glucose in the sample. After the reaction time, the glucose concentration in the sample is displayed on the meter.

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

The current device differs from the predicate in the addition of the radio frequency transmitter to the existing Contour blood glucose monitoring device. The modification does not affect the analytical function of the meter and the current device uses the same test strips and control solutions as cleared in the predicate device in k062058.

# a. Precision/Reproducibility:

Within-run precision was evaluated using venous blood samples at five glucose concentration ranges: 30 - 50, 51 - 110, 111 - 150, 151 - 250 and  $251 - 400\mathrm{mg / dL}$ . Three lot of test strips were tested on 10 meters with 10 replicates per meter  $(N = 100 / \text{lot})$ . Results are summarized below:

{4}

Within-run precision for glucose:

|  Lot | Glucose Level | Mean (mg/dL) | SD (mg/dL) | % CV  |
| --- | --- | --- | --- | --- |
|  1 | 1 | 43.8 | 1.4 | 3.2  |
|   |  2 | 78.4 | 2.6 | 3.4  |
|   |  3 | 129.8 | 3.8 | 2.9  |
|   |  4 | 192.9 | 4.7 | 2.5  |
|   |  5 | 316.2 | 11.6 | 3.7  |
|  Lot | Glucose Level | Mean (mg/dL) | SD (mg/dL) | % CV  |
| --- | --- | --- | --- | --- |
|  2 | 1 | 44.1 | 1.2 | 2.8  |
|   |  2 | 79.2 | 2.7 | 3.4  |
|   |  3 | 130.0 | 3.1 | 2.4  |
|   |  4 | 194.4 | 5.2 | 2.7  |
|   |  5 | 314.2 | 5.4 | 1.7  |
|  Lot | Glucose Level | Mean (mg/dL) | SD (mg/dL) | % CV  |
| --- | --- | --- | --- | --- |
|  3 | 1 | 46.3 | 2.0 | 4.2  |
|   |  2 | 82.1 | 2.2 | 2.6  |
|   |  3 | 130.8 | 5.0 | 3.8  |
|   |  4 | 195.2 | 4.4 | 2.2  |
|   |  5 | 320.0 | 7.3 | 2.3  |

Between-day precision was evaluated using three levels of control solutions. One measurement was taken per meter on 10 meters over the course of 10 days using 3 lots of strips (N = 100). Results are summarized below:

Between-day precision for glucose:

|  Lot | Level | Mean (mg/dL) | SD (mg/dL) | %CV  |
| --- | --- | --- | --- | --- |
|  1 | Low | 40.1 | 0.7 | 1.8  |
|   | Normal | 123.8 | 1.8 | 1.5  |
|   | High | 358.1 | 5.8 | 1.6  |
|  2 | Low | 41.4 | 0.8 | 1.9  |
|   | Normal | 127.0 | 2.7 | 2.1  |
|   | High | 373.4 | 7.1 | 1.9  |
|  3 | Low | 38.3 | 0.8 | 2.1  |
|   | Normal | 119.9 | 1.8 | 1.5  |
|   | High | 350.6 | 6.9 | 2.0  |

b. Linearity/assay reportable range:

Linearity was established in predicate submission (k062058, Bayer's CONTOUR® blood glucose monitoring system). The established linearity in the predicate device was 10-600 mg/dL. The sponsor stated that the new meter has the same hardware or software involved in the measurement of glucose. The difference between the two meters is that the new device is 4 mm thicker to accommodate the new RF transmitter. The claimed linearity for the new

{5}

device is 20-600 mg/dL due to absence of neonatal claim.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability: Traceable to NIST SRM 91, dry D-glucose.

Controls: The controls were cleared under k062058.

Stability: The controls and test strips were cleared under k062058. Stability data was presented and reviewed in k062058.

d. Detection limit:

See linearity section 1. b. above.

e. Analytical specificity:

Interference

As established in predicate k062058. The predicate data was re-evaluated and found to be acceptable.

Additional interference testing was performed on multiple levels (3) of maltose, galactose, xylose, bilirubin, acetaminophen, uric acid and ascorbic acid meeting and exceeding the maximum concentration of the substance expected to be encountered in clinical practice.

The results validate the strip labeling statements:

Strip Labeling Statements:

- Reducing substances occurring in the blood naturally (uric acid, acetaminophen) will not significantly affect results.

- Interference might occur when the values of the limiting concentrations of these compounds are greater than those listed below:
- Bilirubin &gt;20 mg/dL
- Uric Acid &gt;18 mg/dL
- Ascorbic Acid &gt;30 mg/dL
- Acetaminophen &gt;22 mg/dL
- Maltose &gt;200 mg/dL
- Galactose &gt;200 mg/dL

- Xylose: Do not use during or soon after xylose absorption testing.
- Xylose in the blood will cause interference.

6

{6}

f. Assay cut-off:

Not applicable.

## 2. Comparison studies:

a. Method comparison with reference method (Contour Link Wireless versus YSI):

Fingerstick and plasma samples from 100 diabetic subjects were included in the study. In order to fill the bins at the low and high end of the distribution, 19 samples were either glycolyzed to a lower concentration or supplemented with glucose to increase the concentration. 4 measurements were obtained for each sample using two reagent lot and two CONTOUR Link Wireless meters. Plasma samples were also tested in parallel on an YSI 2300 STAT PLUS glucose analyzer, and the result was used as the comparison value. All measurements were performed at $23^{\circ}\mathrm{C} \pm 5^{\circ}\mathrm{C}$.

The distribution of the sample glucose concentrations is specified in the table below.

Sample description:

|  Glucose Concentration (mg/dL) | Number of samples  |   |   |
| --- | --- | --- | --- |
|   |  Total | Fresh Capillary Blood | Manipulated Capillary Blood  |
|  < 50 | 5 | 0 | 5  |
|  51 - 80 | 15 | 9 | 6  |
|  81 - 120 | 20 | 20 | 0  |
|  121 - 200 | 30 | 30 | 0  |
|  201 - 300 | 15 | 15 | 0  |
|  301 - 400 | 10 | 4 | 6  |
|  > 400 | 5 | 3 | 2  |

The ISO 15197 Acceptance Criteria are as follows:

$95\%$ of individual glucose results shall fall within $\pm 15\mathrm{mg / dL}$ (0.83mmol/L) of reference method at glucose concentrations $&lt; 75\mathrm{mg / dL}$ (4.2mmol/L) and within $\pm 20\%$ at glucose concentrations $\geq 75\mathrm{mg / dL}$ (4.2mmol/L).

The results are presented as follows:

Glucose $&lt; 75\mathrm{mg / dL}$ (19 samples)

|  Number of test result | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL  |
| --- | --- | --- | --- |
|  76 | 53 of 76 (69.7%) | 68 of 76 (89.5%) | 75 of 76 (98.7%)  |

{7}

Glucose ≥ 75 mg/dL (81 Samples)

|  Number of test results | Within ± 5 % | Within ± 10 % | Within ± 15% | Within ± 20%  |
| --- | --- | --- | --- | --- |
|  324 | 177 of 324 (54.6 %) | 276 of 324 (85.2 %) | 312 of 324 (96.3 %) | 319 of 324 (98.5 %)  |

Summary Assessment of Accuracy (100 Samples)

|  Number of test results | Readings within ±15 mg/dL if <75 mg/dL, ±20% if ≥75 mg/dL  |
| --- | --- |
|  400 | 98.5% (394 of 400)  |

## b. User performance study

As established in the predicate device cleared under k062058.

## c. Matrix comparison:

Not applicable. Only capillary whole blood samples are acceptable matrix.

## 3. Clinical studies:

a. Clinical Sensitivity:

Not applicable.

b. Clinical specificity:

Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

## 4. Clinical cut-off:

Not applicable.

## 5. Expected values/Reference range:

The following is stated in the labeling:

"Blood sugar values will vary depending on food intake, medication dosages, health, stress, or activity. Non diabetic plasma glucose concentrations are normally maintained within a relatively narrow 70-110 mg/dL in the fasting state. You should consult with your healthcare provider for expected glucose values specific to your

{8}

needs."

¹ Longo DL, et al.: Harrison's Principles of Internal Medicine-18th edition, 2011:3003.

## N. Instrument Name:

CONTOUR® Link Wireless Blood Glucose Meter

## O. System Descriptions:

1. **Modes of Operation:**

Each test strip is single use and requires a sample volume of 0.6 uL.

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?

Yes ☐ X ☐ or No ☐

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?

Yes ☐ X ☐ or No ☐

2. **Software:**

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes ☐ X ☐ or No ☐

3. **Specimen Identification:**

There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.

4. **Specimen Sampling and Handling:**

The glucose test is intended to be used with capillary whole blood from the finger only. The whole blood sample is applied directly to the test strip by capillary action.

5. **Calibration:**

There is no calibration required for the CONTOUR® Link Wireless Blood Glucose Meter by the user. The meter is automatically coded.

{9}

6. Quality Control:

Glucose control solutions at three different concentrations can be used with this device. The meter automatically distinguishes control solution from blood and marks control solution tests with a check mark and excludes them from average calculations. Recommendations on when to test the control materials are provided in the labeling. An acceptable range for each control level is printed on the control solutions vial label. The user is cautioned not to use the meter if the control result falls outside these ranges.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:

1. Flesch-Kincaid readability assessment was conducted and the results showed that the labeling (User Guide, test strip package insert and control solution package insert) were written at the 8th grade level.

2. Customer service is available 24/7, 365 days a year. Toll free phone number is 1-800-348-8100 for Bayer Diabetes Care customer support.

3. Temperature and humidity operating conditions were evaluated for temperatures ranging from 41°F-113°F (5°C to 45°C) and relative humidity from 10% to 93%. Protocol and acceptance criteria were provided and found to be acceptable. The results supported the Sponsor's claimed operating temperature from 41°F-113°F and relative humidity range from 10% to 93%.

4. EMC testing was performed on the CONTOUR® Link Wireless Blood Glucose Meter by an accredited EMC Testing Laboratory LS Research, LLC. A letter of attestation was issued to Bayer on October 12, 2007.

5. The sponsor claims that the current device can be used at altitudes up to 11,000 feet based on the study performed on the predicate meter cleared in k062058.

6. The sponsor performed hematocrit studies on five Contour® Link Wireless meters using 6 different hematocrit levels (15, 20, 25, 30, 42, 55 and 65%) across 5 glucose concentrations (40, 80, 120, 350, 500 mg/dL). At each hematocrit level, samples at various glucose concentrations were tested against the YSI method. The bias of all test results were less than 10 mg/dL (at glucose &lt; 100 mg/dL) or less than 10% (at glucose ≥ 100 mg/dL) compared to YSI method, therefore the sponsor claims that hematocrit between 20% to 65% does not significantly affect the glucose results.

7. Disinfection and Robustness studies:

The device is intended for single-patient use only. Clorox® Germicidal Wipes containing 0.55% sodium hypochlorite with EPA registration # 67619-12 was validated demonstrating complete inactivation of live virus using materials used in the meter and lancing device. The sponsor also demonstrated that there

10

{10}

was no change in performance or in the external materials of the meter and lancing device after 260 cleaning and disinfection cycles designed to simulate cleaning and disinfection 1x per week for 5 years. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.

8. The software changes related to the modified functions (Bluetooth data transmission and memory storage of up to 1000 tests) were tested and the intended functions were validated.

Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

11

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/LFR/K110587](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/LFR/K110587)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com